Investing Experience -
Risk Profile -
Followers
0
Following
0
Blog Posts
0
Threads
94
Blogs
Threads
Portfolio
Follower
Following
Summary
Total comments
94
Past 30 days
0
Past 7 days
0
Today
0
User Comments
Stock
Stock
Stock
Stock
Stock
Stock
Stock
Stock
Stock
Stock
Stock
2021-03-09 08:35 | Report Abuse
proven vaccine is good for solution to sell in asean
Stock
2021-03-09 08:32 | Report Abuse
PUTRAJAYA (March 8): National Covid-19 Immunisation Programme Coordinating Minister Khairy Jamaluddin said Malaysia may look to procure the single-dose CanSino Covid-19 vaccine from China.
Stock
Stock
Stock
2021-01-22 08:32 | Report Abuse
Sub Biz 22.1.2021
Bintai Kinden to diversify into property sector
PETALING JAYA: Bintai Kinden Corp Bhd has proposed a diversification into the property development and management business and intends to undertake two mixed property development and management projects – Holistica Melaka and Holistica Penang.
At present, Bintai Kinden and its subsidiaries are principally involved in the provision of specialised mechanical & electrical (M&E) engineering, provision of turnkey, structural, civil, infrastructure project and project management, concessionaire arrangements and trading activities.
The two mixed property development and management projects that it plans to undertake will be designed to provide a holistic living environment, with a focus on providing comprehensive healthcare and wellness services as well as assisted living for better community lifestyle.
Holistica Melaka is an integrated holistic and wellness themed project which will comprise wellness condotels, wellness condominiums, retirement and lifestyle apartments, wellness club as well a medical specialist centre measuring 4.744 acres, with a gross development value (GDV) of RM558 million.
Holistica Penang is a 21-storey lifestyle condotel in George Town, Penang, measuring 0.598 acres, with a GDV of RM83.7 million.
“The mixed development projects are expected to contribute 25% or more of the net assets and/or net profits of the Bintai group. As such, the board proposes to seek the prior approval from the shareholders of the company at an EGM to be convened for the proposed diversification.
The board intends to continue with the group’s existing business activities, Bintai Kinden said.
The expansion of Bintai Kinden group’s property development business segment is part of the company’s strategy of diversifying into other industries with strong growth prospects instead of depending solely on its existing core M&E engineering business. The group has past experiences and expertise in undertaking and completing various construction of property development and related projects across a span of 36 years.
The board believes that the mixed development projects would contribute positively to future earnings and improve the financial position of the Bintai Kinden group.
Bintai Kinden also proposed a private placement of up to 30% of its existing issued shares at an indicative issue price of 52 sen per share, to independent investors to be identified later, to raise RM58.43 million. The proceeds will be used mainly for the mixed development projects.
The proposals are expected to be completed by the second quarter of 2021.
Stock
2021-01-07 08:34 | Report Abuse
"the supply would not be enough for everyone in the near future,” Boo said."
Stock
2021-01-07 08:33 | Report Abuse
7.1.2021
http://ipaper.thesundaily.my/epaper/viewer.aspx?publication=The%20Sun%20Daily#page/12
Yong Tai finalises plans for Covid vaccine commercialisation
PETALING JAYA: Yong Tai Bhd is finalising its plans for the commercialisation of Covid-19 vaccine with Shenzhen Kangtai Biological Products Co Ltd (SZKT) through its latest partnerships with Tiong Nam Logistics Solutions Sdn Bhd and Healthcliqs Sdn Bhd.
Yong Tai has put into motions its plan for the distribution of vaccine by engaging Tiong Nam to provide total logistics services which include transportation, warehouse space and distribution of the pharmaceutical products.
Aside from that, the group would also collaborate with Healthcliqs, a digital healthcare solution, which would facilitate Yong Tai in getting immediate access to more than 4,000 general practitioners nationwide for the marketing of its medical products.
Yesterday, Yong Tai’s 70%-owned subsidiary YTB Healthcare Sdn Bhd (YTBH) entered into a collaboration agreement for logistic services with Tiong Nam. YTBH also entered into a service provider agreement with Healthcliqs to engage Healthcliqs as service provider for the provision of services which include promotional sales campaign, marketing activities and virtual sales representation services of the vaccine.
According to Yong Tai CEO Datuk Wira Boo Kuang Loon (pix), these partnerships would help Yong Tai to have an immediate access to the market that needs the vaccine as well as the critical storage and logistic services for the delivery of vaccine, upon the successful phase III clinical trial and registration with the relevant authorities.
“We think that it provides us the opportunity to diversify our business away from the tourism and property segment. A lot of planning has been done and we will be investing about RM15 to RM20 million into the phase III clinical trial of the vaccine. While there are other vaccines in the market already such as the one developed by Pfizer, AstraZeneca Plc and even China’s Sinovac Biotech Ltd, the supply would not be enough for everyone in the near future,” Boo said.
Yong Tai and SZKT are in the final milestone to wrap up its definitive agreement and it is likely to be signed soon now that both the logistics and marketing plans are in place. Both parties state the collaboration can ensure a minimum supply of 20 million doses.
Stock
2020-12-17 12:26 | Report Abuse
https://www.ibtimes.com/
Swathes Of Globe May Not Get Vaccine Until 2022: Study
By Kelly MACNAMARA
12/15/20 AT 8:09 PM
At least a fifth of the world's population may not have access to a Covid-19 vaccine until 2022, according to a study published Wednesday, with wealthier nations reserving more than half of next year's potential doses.
With hopes that vaccines can bring an end to a pandemic that has killed some 1.6 million people, countries including the United States, Britain and the United Arab Emirates have already begun rolling out immunisation programmes.
Eager to increase their chances of having access to at least one of the dozens of vaccines in development, many nations have snapped up allocations of several different drugs.
Wealthy nations -- accounting for just 14 percent of the global population -- have pre-ordered just over half of the vaccine doses expected to be produced by the 13 leading developers next year, researchers from the Johns Hopkins Bloomberg School of Public Health found.
There are fears that poorer nations will be left behind.
Even if the drug makers all produce effective, safe vaccines and meet their maximum global manufacturing targets, the study said "at least a fifth of the world's population would not have access to vaccines until 2022".
The research, published in the BMJ medical journal, looked at publicly available data and found that as of mid-November, reservations totalled 7.48 billion doses -- equivalent to 3.76 billion immunisation courses, because most vaccines require two jabs.
Stock
2020-12-13 15:10 | Report Abuse
The Star today
TANGKAK, 13 Dis — Kerajaan bercadang meningkatkan pembelian vaksin COVID-19 agar dapat menampung keperluan imunisasi hingga 70 peratus rakyat berbanding kuantiti asal sebanyak 30 peratus, kata Perdana Menteri Tan Sri Muhyiddin Yassin.
Beliau berkata ini kerana ada negara yang sudah membeli vaksin itu dengan sesetengahnya memperoleh dalam kuantiti yang banyak melebihi jumlah penduduk mereka sendiri.
“Untuk keperluan Malaysia, kita sudah dapat 30 peratus. Saya sudah arahkan Menteri Kesihatan Datuk Seri Dr Adham Baba bersama (Menteri Sains, Teknologi dan Inovasi) Khairy Jamaluddin untuk berunding supaya dapat tambah dari 30 peratus kepada 60 ataupun 70 peratus.
“Ini dinasihatkan oleh Kementerian Kesihatan Malaysia setakat hari ini… kalau dapat ditingkatkan ke jumlah itu maka lebih terjamin rakyat kita daripada virus COVID-19,” katanya ketika berucap pada Majlis Sambutan Deepavali 2020 Dewan Undangan Negeri Gambir, di sini hari ini.
Muhyiddin yang juga Ahli Dewan Undangan Negeri Gambir berkata beliau telah meminta pembekal menghantar vaksin tersebut secepat mungkin dan Malaysia dijangka menerima bekalan pada Mac tahun depan.
“Berkesan tak berkesan, jangan sampai rakyat marah perdana menteri (sebab tidak beli)… orang lain sudah beli, saya pun beli juga… cepat-cepat kita beli.. (vaksin) akan sampai bulan tiga tahun depan,” katanya.
Pada 24 Nov lalu, Malaysia mengumumkan bahawa ia akan mendapatkan bekalan awal sebanyak 12.8 juta dos vaksin COVID-19 daripada syarikat farmaseutikal Pfizer bagi menampung keperluan imunisasi 20 peratus atau 6.4 juta rakyat negara ini secara percuma.
Dua hari sebelum itu, Malaysia memeterai perjanjian dengan fasiliti COVAX untuk memperoleh bekalan vaksin tersebut bagi menampung keperluan imunisasi 10 peratus lagi rakyat negara ini.
Sementara itu, perdana menteri mengarahkan agar hospital sementara merawat COVID-19 dibuka semula berikutan peningkatan secara berterusan kes baharu di beberapa negeri seperti Selangor, Wilayah Persekutuan Kuala Lumpur, Negeri Sembilan dan Johor.
“Ini bermakna walaupun langkah yang kerajaan ambil agak berkesan dari satu sudut, kalau dibandingkan dengan negara-negara lain kita belum dapat mengatasinya.
“Kita belum berjaya melandaikan lekuk COVID-19,” katanya, menambah perkara itu dijangka mengambil masa yang lama.
Ahli Parlimen Pagoh itu berkata sejak hari pertama menjadi perdana menteri, beliau belum lagi dapat berehat memandangkan negara masih dalam ancaman.
“Selagi rakyat kita terancam dan diancam dengan penyakit COVID-19, saya tidak akan berehat. Saya akan bekerja… menguruskan COVID-19, menguruskan ekonomi negara,” kata Muhyiddin.
Sementara itu, perdana menteri berkata kerajaan sedang menjalankan satu kajian menyeluruh mengenai peratusan sebenar rakyat yang jatuh ke paras garis kemiskinan akibat COVID-19.
“Sekarang ini paras garis kemiskinan sudah naik kepada RM2,208 per kapita. Bila sudah naik, lebih ramai rakyat kita yang tergolong dalam kumpulan B40 itu, golongan yang agak miskin dan miskin tegar.
“Bila COVID-19 berlaku, ramai orang yang tidak bekerja, tidak boleh berniaga, buka warung pun tak boleh, pendapatan merosot… syarikat tidak ambil lagi pekerja,” katanya.
Sumber: BERNAMA
Stock
Stock
2020-12-07 19:05 | Report Abuse
Succeeding the former IGP as Inix's chairman will be Tan Sri Syed Mohd Yusof Tun Syed Nasir. The 73-year-old was previously chairman of YLI Holdings Bhd — a post he relinquished in January.
Stock
2020-12-07 19:04 | Report Abuse
Inix chairman ex-IGP Mohamad Fuzi Harun quits five days after appointment
Arjuna Chandran Shankar
/
theedgemarkets.com
December 07, 2020 18:41 pm +08
Stock
2020-12-07 08:42 | Report Abuse
The Sun
7.12.2020
Who’s who in Covid-19 vaccine play
A growing number of Bursa-listed companies have entered into manufacturing and distribution deals
BY AMIR IMRAN HUSAIN SAFRI
sunbiz@thesundaily.com
PETALING JAYA: The ongoing Covid-19 pandemic has dictated the performance of the global economy for the majority of 2020. In the early days of the novel coronavirus outbreak, there were a number of companies that jumped on the glove-manufacturing bandwagon, and now with positive news on vaccine development, several more Bursa Malaysia-listed companies are entering the vaccine manufacturing and distribution business.
Making the list of Bursa-listed companies in the vaccine effort is Kanger International Bhd, which joined the foray in September via an agreement with Shenzhen Public Health Technology Co Ltd to secure a dealership/distributorship from China National Pharmaceutical Group Corp’s (Sinopharm) potential vaccine.
Since its initial announcement, the group has entered into two separate agreements with Zuellig Pharma Sdn Bhd and K-Star Sport Ltd for the distribution of Covid-19 vaccine in Malaysia and subsequently received no objections by the Science, Technology and Innovation Ministry (Mosti) for the purchase of vaccine for private sector use in the country.
Similarly, Metronic Global Bhd entered into a memorandum of agreement with Taiwan-listed pharmaceutical company, Medigen Vaccine Biologics Corp for its Covid-19 vaccine, via its subsidiary, Metronic Medicare Sdn Bhd.
Before the group can commence the distributorship, it has to secure a pharmaceutical good distribution practice certification with the National Pharmaceutical Regulatory Agency and register the product with the agency, which entails a full evaluation of the vaccine, including local clinical trials. It expects to submit the documents by 2022/2023.
From the vaccine, Metronic has projected an estimated gross profit of RM120 million to RM180 million based on a price assumption of US$50 per dose and an estimated industry wide gross margin of 20% to 30%.
Bintai Kinden Corp entered into a framework agreement for the development and commercialisation of the Ii-Key-SARS-CoV-2 coronavirus vaccine in China with Chinese Center for Disease Control and Prevention (China CDC), Beijing Guoxin Haixiang Equity Investment Partnership and Beijing Youfeng International Consulting Co Ltd via its partner, Generex Biotechnology Corp in November.
Subsequently, Generex has signed a US$50 million licensing and development deal for the exclusive use of its vaccine platform technology for infectious disease and cancer in China and its territories.
Under the agreement , Bintai is granted exclusive rights to distribute, sell and commercialise the Covid-19 vaccine in Malaysia, Brunei, Myanmar, Cambodia, Timor-Leste, Indonesia, Laos, the Philippines, Singapore, Thailand and Vietnam. It also has the right of first refusal to commercially exploit the vaccine in New Zealand, Australia and the global halal market.
Ho Wah Genting has also ventured into vaccine play through its collaboration with US-based E-MO Biology Inc (EBI). In November, its vaccine received approval by the US Food & Drug Administration to begin phase IV clinical trials.
The group has also entered into a memorandum of understanding with China’s Xinkexian (Beijing) Biotechnology Co Ltd to appoint the latter as a non-exclusive manufacturer for the vaccine related to the Covid-19 virus, which is contingent on EBI’s successful completion of clinical trials.
DKSH Holdings (Malaysia) Bhd, too, is seen as a possible beneficiary of the vaccine development play, due to its long-term relationships with AstraZeneca and Pfizer, which are front runners in the global vaccine race. Given its established links with the two front runners, there is a probability that the group will be involved in its distribution when the vaccine becomes commercially available.
Similarly, government-linked counters, Pharmaniaga Bhd and Duopharma Biotech Bhd have been identified by the government as pharmaceutical players with the capacity to undertake fill-finish processing for any Covid-19 vaccine.
Given the scale of the pandemic, MIDF Research’s head of research Imran Yassin believes the vaccine will not be reduced to one or two types coming from one or two players.
“Here, we believe that it is a case of more is better. In terms of involvement, again we believe that there will not be one type of involvement which is the best,” he told SunBiz.
Imran opined that any involvement in the value chain will be critical as this is a health crisis, first and foremost.
Stock
2020-12-07 08:41 | Report Abuse
The Sun
7.12.2020
Who’s who in Covid-19 vaccine play
A growing number of Bursa-listed companies have entered into manufacturing and distribution deals
BY AMIR IMRAN HUSAIN SAFRI
sunbiz@thesundaily.com
PETALING JAYA: The ongoing Covid-19 pandemic has dictated the performance of the global economy for the majority of 2020. In the early days of the novel coronavirus outbreak, there were a number of companies that jumped on the glove-manufacturing bandwagon, and now with positive news on vaccine development, several more Bursa Malaysia-listed companies are entering the vaccine manufacturing and distribution business.
Making the list of Bursa-listed companies in the vaccine effort is Kanger International Bhd, which joined the foray in September via an agreement with Shenzhen Public Health Technology Co Ltd to secure a dealership/distributorship from China National Pharmaceutical Group Corp’s (Sinopharm) potential vaccine.
Since its initial announcement, the group has entered into two separate agreements with Zuellig Pharma Sdn Bhd and K-Star Sport Ltd for the distribution of Covid-19 vaccine in Malaysia and subsequently received no objections by the Science, Technology and Innovation Ministry (Mosti) for the purchase of vaccine for private sector use in the country.
Similarly, Metronic Global Bhd entered into a memorandum of agreement with Taiwan-listed pharmaceutical company, Medigen Vaccine Biologics Corp for its Covid-19 vaccine, via its subsidiary, Metronic Medicare Sdn Bhd.
Before the group can commence the distributorship, it has to secure a pharmaceutical good distribution practice certification with the National Pharmaceutical Regulatory Agency and register the product with the agency, which entails a full evaluation of the vaccine, including local clinical trials. It expects to submit the documents by 2022/2023.
From the vaccine, Metronic has projected an estimated gross profit of RM120 million to RM180 million based on a price assumption of US$50 per dose and an estimated industry wide gross margin of 20% to 30%.
Bintai Kinden Corp entered into a framework agreement for the development and commercialisation of the Ii-Key-SARS-CoV-2 coronavirus vaccine in China with Chinese Center for Disease Control and Prevention (China CDC), Beijing Guoxin Haixiang Equity Investment Partnership and Beijing Youfeng International Consulting Co Ltd via its partner, Generex Biotechnology Corp in November.
Subsequently, Generex has signed a US$50 million licensing and development deal for the exclusive use of its vaccine platform technology for infectious disease and cancer in China and its territories.
Under the agreement , Bintai is granted exclusive rights to distribute, sell and commercialise the Covid-19 vaccine in Malaysia, Brunei, Myanmar, Cambodia, Timor-Leste, Indonesia, Laos, the Philippines, Singapore, Thailand and Vietnam. It also has the right of first refusal to commercially exploit the vaccine in New Zealand, Australia and the global halal market.
Ho Wah Genting has also ventured into vaccine play through its collaboration with US-based E-MO Biology Inc (EBI). In November, its vaccine received approval by the US Food & Drug Administration to begin phase IV clinical trials.
The group has also entered into a memorandum of understanding with China’s Xinkexian (Beijing) Biotechnology Co Ltd to appoint the latter as a non-exclusive manufacturer for the vaccine related to the Covid-19 virus, which is contingent on EBI’s successful completion of clinical trials.
DKSH Holdings (Malaysia) Bhd, too, is seen as a possible beneficiary of the vaccine development play, due to its long-term relationships with AstraZeneca and Pfizer, which are front runners in the global vaccine race. Given its established links with the two front runners, there is a probability that the group will be involved in its distribution when the vaccine becomes commercially available.
Similarly, government-linked counters, Pharmaniaga Bhd and Duopharma Biotech Bhd have been identified by the government as pharmaceutical players with the capacity to undertake fill-finish processing for any Covid-19 vaccine.
Given the scale of the pandemic, MIDF Research’s head of research Imran Yassin believes the vaccine will not be reduced to one or two types coming from one or two players.
“Here, we believe that it is a case of more is better. In terms of involvement, again we believe that there will not be one type of involvement which is the best,” he told SunBiz.
Imran opined that any involvement in the value chain will be critical as this is a health crisis, first and foremost.
Stock
2020-12-07 08:41 | Report Abuse
The Sun
7.12.2020
Who’s who in Covid-19 vaccine play
A growing number of Bursa-listed companies have entered into manufacturing and distribution deals
BY AMIR IMRAN HUSAIN SAFRI
sunbiz@thesundaily.com
PETALING JAYA: The ongoing Covid-19 pandemic has dictated the performance of the global economy for the majority of 2020. In the early days of the novel coronavirus outbreak, there were a number of companies that jumped on the glove-manufacturing bandwagon, and now with positive news on vaccine development, several more Bursa Malaysia-listed companies are entering the vaccine manufacturing and distribution business.
Making the list of Bursa-listed companies in the vaccine effort is Kanger International Bhd, which joined the foray in September via an agreement with Shenzhen Public Health Technology Co Ltd to secure a dealership/distributorship from China National Pharmaceutical Group Corp’s (Sinopharm) potential vaccine.
Since its initial announcement, the group has entered into two separate agreements with Zuellig Pharma Sdn Bhd and K-Star Sport Ltd for the distribution of Covid-19 vaccine in Malaysia and subsequently received no objections by the Science, Technology and Innovation Ministry (Mosti) for the purchase of vaccine for private sector use in the country.
Similarly, Metronic Global Bhd entered into a memorandum of agreement with Taiwan-listed pharmaceutical company, Medigen Vaccine Biologics Corp for its Covid-19 vaccine, via its subsidiary, Metronic Medicare Sdn Bhd.
Before the group can commence the distributorship, it has to secure a pharmaceutical good distribution practice certification with the National Pharmaceutical Regulatory Agency and register the product with the agency, which entails a full evaluation of the vaccine, including local clinical trials. It expects to submit the documents by 2022/2023.
From the vaccine, Metronic has projected an estimated gross profit of RM120 million to RM180 million based on a price assumption of US$50 per dose and an estimated industry wide gross margin of 20% to 30%.
Bintai Kinden Corp entered into a framework agreement for the development and commercialisation of the Ii-Key-SARS-CoV-2 coronavirus vaccine in China with Chinese Center for Disease Control and Prevention (China CDC), Beijing Guoxin Haixiang Equity Investment Partnership and Beijing Youfeng International Consulting Co Ltd via its partner, Generex Biotechnology Corp in November.
Subsequently, Generex has signed a US$50 million licensing and development deal for the exclusive use of its vaccine platform technology for infectious disease and cancer in China and its territories.
Under the agreement , Bintai is granted exclusive rights to distribute, sell and commercialise the Covid-19 vaccine in Malaysia, Brunei, Myanmar, Cambodia, Timor-Leste, Indonesia, Laos, the Philippines, Singapore, Thailand and Vietnam. It also has the right of first refusal to commercially exploit the vaccine in New Zealand, Australia and the global halal market.
Ho Wah Genting has also ventured into vaccine play through its collaboration with US-based E-MO Biology Inc (EBI). In November, its vaccine received approval by the US Food & Drug Administration to begin phase IV clinical trials.
The group has also entered into a memorandum of understanding with China’s Xinkexian (Beijing) Biotechnology Co Ltd to appoint the latter as a non-exclusive manufacturer for the vaccine related to the Covid-19 virus, which is contingent on EBI’s successful completion of clinical trials.
DKSH Holdings (Malaysia) Bhd, too, is seen as a possible beneficiary of the vaccine development play, due to its long-term relationships with AstraZeneca and Pfizer, which are front runners in the global vaccine race. Given its established links with the two front runners, there is a probability that the group will be involved in its distribution when the vaccine becomes commercially available.
Similarly, government-linked counters, Pharmaniaga Bhd and Duopharma Biotech Bhd have been identified by the government as pharmaceutical players with the capacity to undertake fill-finish processing for any Covid-19 vaccine.
Given the scale of the pandemic, MIDF Research’s head of research Imran Yassin believes the vaccine will not be reduced to one or two types coming from one or two players.
“Here, we believe that it is a case of more is better. In terms of involvement, again we believe that there will not be one type of involvement which is the best,” he told SunBiz.
Imran opined that any involvement in the value chain will be critical as this is a health crisis, first and foremost.
Stock
2020-11-30 21:00 | Report Abuse
Look at the future prospect instead of qovid era q
Stock
Stock
Stock
2020-11-16 08:48 | Report Abuse
PETALING JAYA: mTouche Technology Bhd said a number of its novel coronavirus RT-PCR detection and diagnostic kits have been assessed and have received final decision and approval by the Medical Device Authority (MDA), under the purview of the Health Ministry (MoH), and are now “recommended for use”.
Stock
2020-11-16 08:48 | Report Abuse
http://ipaper.thesundaily.my/epaper/viewer.aspx?publication=The%20Sun%20Daily#page/12
mTouche: Medical Devices Authority nod for certain Covid-19 test kits
Stock
2020-11-07 17:30 | Report Abuse
Conditional MCO in all states in Peninsular M'sia except Kelantan, Pahang, Perlis from Nov 9-Dec 6 (updated)
NATION
Saturday, 07 Nov 2020
4:38 PM MYT
https://www.thestar.com.my/
Stock
Stock
Stock
2020-08-25 11:00 | Report Abuse
25 August 2020
Frontpage
1
News without Borders
234567
Speak Up
89
Media & Marketing
10
Sunbiz
11121314
Grad+
1516
Entertainment
17
Going Places
18
Youth
19
Feature
20
Sports
21222324
Karex expands into glove-making business
Group will build a plant at its Thai subsidiary in Hat Yai, production to start within 12 months
PETALING JAYA: Karex Bhd is venturing into the manufacturing and sale of gloves through its wholly owned subsidiary Innolatex (Thailand) Limited (ITL).
The group plans to establish a new manufacturing facility to supplement its existing operations at ITL’s plant in Hat Yai, Thailand with an eventual planned capacity of up to 2.5 billion gloves annually.
“Karex intends to manufacture and sell medical gloves that are typically worn by healthcare professionals and workers in the medical field. The medical gloves are intended to be made from nitrile, natural rubber and any other new materials that may be developed by Karex’s research and development efforts,“ Karex said in a stock exchange filing yesterday.
ITL currently manufactures condoms, personal lubricants and other rubber products including catheters. The new manufacturing facility for the manufacturing of medical gloves will not affect the current prodcution capacity of ITL.
At the initial stage, Karex intends to set up two production lines within 12 months which is estimated to have a yearly production capacity of up to 500 million gloves (Phase 1) with the remaining production lines to be gradually set up over the course of the next 48 months.
The manufacture and sale of gloves is expected to commence commercial production within 12 months.
Karex will require a total estimated capital expenditure of RM40 million in Phase 1 which will be funded through a combination of internally generated funds and/or bank borrowings.
In addition, the manufacture and sale of gloves is expected to offer an additional complimentary line of products within Karex’s existing medical business segment that currently consists of catheters, ultrasonic probe covers, test kits and hand sanitisers.
Karex posted a net profit of RM1.43 million in its fourth quarter ended June 30, compared with a net loss of RM1.01 million a year ago, while revenue rose 3.9% to RM91.09 million from RM87.66 million sustained through an increased contribution from the sexual wellness segment.
For the full year period, its net profit was 11 times lower at RM228,000 from RM2.53 million a year ago, due to higher tax expenses, while revenue rose 4.4% to RM395.07 million from RM378.48 million.
Karex said the ongoing Covid-19 pandemic has presented a unique challenge to the sexual health and medical devices industries causing widespread disruptions to operations and supply chains. Along with the emphasis on social compliance, this has caused consolidation in the industry and a disruption to the supply of condoms globally.
“In spite of this, condoms remain an essential tool for family planning as well as preventing the spread of HIV and other sexually transmitted infections. The group remains confident that we are uniquely poised to overcome the aforementioned operation hurdles in order to take advantage of potential opportunities presented by the renewed global emphasis on hygiene and disease prevention.”
Search text
All the editions
Date of Search
All the dates
Search
Stock
2020-08-05 10:06 | Report Abuse
Frontpage
1
News without Borders
23456
Advertisement
7
News without Borders
8
Speak Up
9
Media & Marketing
10
Sunbiz
11121314
Lifestyle
15
Fashion
16
Beauty
17
The right read
18
Feature
1920
Sports
21222324
No likelihood of ‘silver bullet’ vaccine, says WHO
Global health authority urges countries to continue disease control procedures
GENEVA/PARIS: Dashing high hopes for the Covid-19 vaccine, the World Health Organisation said that there may never be a “silver bullet” answer to the new coronavirus.
“We hope to have a number of effective vaccines that can help prevent people from infection.
“However, there’s no silver bullet at the moment and there might never be,” WHO director-general Tedros Adhanom said during an online press conference in Geneva on Monday.
Tedros’ statement comes as health experts across the world race to develop antidotes for the deadly disease.
The WHO chief also exhorted countries and citizens to continue to follow the basics, such as testing, contact tracing, practicing social distancing and wearing a mask to contain the spread of the pandemic which has thrown normal life out of gear around the globe.
“For now, stopping outbreaks comes down to the basics of public health and disease control. Do it all.”
The pandemic has killed at least 690,000 people worldwide, with more than 18 million people infected, according to an AFP tally on Monday based on official sources.
The United States had the most deaths with 154,944, followed by Brazil with 94,104, Mexico 47,746, the United Kingdom with 46,210 and India with 38,135 fatalities.
Belgium had the highest per capita death rate, with 849 per million of the population.
In the Philippines capital Manila, four provinces in Luzon was back under lockdown from yesterday, a measure affecting 27 million people.
Since the beginning of June, when much of the country emerged from one of the world’s longest stay-at-home orders, confirmed infections in the archipelago have increased fivefold, surging past 100,000.
Meanwhile, Norway announced restrictions on cruises along its coast after dozens were infected with coronavirus on board a ship run by Hurtigruten, which suspended its operations.
Health authorities fear the ship also could have spread the virus to dozens of towns and villages along Norway’s western coast.
Russia said it aimed to launch mass production of a coronavirus vaccine next month and turn out “several million” doses per month by next year.
The country is pushing ahead with several prototypes and officials said that one, prepared at the Gamaleya institute in Moscow, has reached advanced stages of development. – Agencies
Search text
All the editions
Date of Search
All the dates
Search
Stock
Stock
Stock
Stock
2020-07-30 11:05 | Report Abuse
DG: Face masks may be compulsory once out of home
Published on 29 Jul 2020 9:59:04 PM
It may be compulsory for the public to wear face masks when they leave their homes.
"But masks must be made available to the needy first. Everyone must have excess to a face mask," Health director-general Datuk Dr Noor Hisham Abdullah said at an engagement session with the media on Wednesday.
The authorities have already announced that face masks will be compulsory at public and crowded areas from Aug 1.
WATCH MORE: https://thestartv.com/c/news
SUBSCRIBE: https://cutt.ly/TheStar
LIKE: https://fb.com/TheStarOnline
Stock
Stock
2020-07-16 08:30 | Report Abuse
If you rely only from the past, the there are many other good counter like that but with no price movements at all. It takes forever to move.
Stock
2020-06-23 07:40 | Report Abuse
Investinside, what focal is. I am new.
Stock
Stock
2020-06-22 15:52 | Report Abuse
GE 15 is around the corner. Will shoot to 40 cts
Stock
Stock
2018-10-17 17:24 | Report Abuse
New KL Mayor is Ex Selayang Municipal President. He is pro projects in Selayang, including KL North Gate, which is ANZA's. Will shoot. Dont wait
Stock
Stock
Stock
2018-01-10 10:25 | Report Abuse
Wednesday, 10 Jan 2018
KUALA LUMPUR: Daya Materials Bhd
image: https://cdn.thestar.com.my/
KUALA LUMPUR: Daya Materials Bhd’s unit Daya Secadyme Sdn Bhd has received a three-year contract to supply and deliver specialty chemicals to Petroliam Nasional Bhd (Petronas).
Stock: [BINTAI]: BINTAI KINDEN CORPORATION BHD
2021-11-26 17:03 | Report Abuse
https://www.klsescreener.com/v2/news/view/915149/bintai-kinden-returns-to-the-black-with-a-net-profit-of-rm511-000-for-q2#:~:text=For%20the%20cumulative%20six-month%20period%2C%20Bintai%20Kinden%20registered,per%20cent%20to%20RM29.41%20million%20from%20RM25.97%20million.